ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on X

Kidney Week

Abstract: FR-PO0444

Calciphylaxis Beyond Dialysis: Real-World Comparative Analysis of Outcomes in ESRD and Advanced Nondialysis-Dependent CKD

Session Information

Category: Dialysis

  • 801 Dialysis: Hemodialysis and Frequent Dialysis

Authors

  • Matarneh, Ahmad, Penn State Health Milton S Hershey Medical Center, Hershey, Pennsylvania, United States
  • Matarneh, Bayan, Penn State Health Milton S Hershey Medical Center, Hershey, Pennsylvania, United States
  • Sardar, Sundus, Penn State Health Milton S Hershey Medical Center, Hershey, Pennsylvania, United States
  • Salameh, Omar Khaleel Mohammad, Penn State Health Milton S Hershey Medical Center, Hershey, Pennsylvania, United States
  • Verma, Navin, Penn State Health Milton S Hershey Medical Center, Hershey, Pennsylvania, United States
  • Ghahramani, Nasrollah, Penn State Health Milton S Hershey Medical Center, Hershey, Pennsylvania, United States
Background

Calciphylaxis is classically linked to end-stage renal disease (ESRD) requiring dialysis, but increasing reports describe its occurrence in patients with advanced non-dialysis chronic kidney disease (CKD). However, comparative incidence and outcomes in these populations remain poorly characterized in large real-world datasets.

Methods

We queried the TriNetX Global Collaborative Network, which includes data from 148 healthcare organizations, to identify adults (≥18 years) with either:
Cohort A: ESRD receiving dialysis
Cohort B: Stage 4–5 CKD not on dialysis
between 2005 and 2025.
Calciphylaxis was identified using ICD-10 code E83.59. Patients were followed for one year after diagnosis for outcomes including all-cause mortality, limb amputation, and sepsis. Risk ratios (RR), odds ratios (OR), and Kaplan-Meier survival analyses were conducted without propensity matching.

Results

We identified 503,864 patients with ESRD and 685,346 with stage 4–5 CKD not on dialysis. Calciphylaxis was diagnosed in:
1.5% of ESRD patients vs. 0.5% of non-dialysis CKD patients
RR: 3.25; OR: 3.28; p<0.001
Following calciphylaxis diagnosis:
Mortality was high in both groups
Amputation occurred in 1.4% (ESRD) vs. 0.4% (CKD); OR: 3.27
Sepsis occurred in 19.3% (ESRD) vs. 12.3% (CKD); OR: 1.71
Kaplan-Meier curves showed significantly lower event-free survival in the ESRD cohort, but the non-dialysis CKD group also experienced substantial morbidity and mortality.

Conclusion

Calciphylaxis is not limited to dialysis-dependent individuals. While less frequent in patients with non-dialysis advanced CKD, outcomes including mortality, infection, and limb loss remain severe. These findings underscore the need for increased awareness, early recognition, and preventive efforts in high-risk CKD populations irrespective of dialysis status.

Digital Object Identifier (DOI)